TetraLogic Pharmaceuticals Announces Presentation of Preclinical Data on Birinapant (TL32711) in Pancreatic Cancer and Lymphoma at the 103rd AACR Annual Meeting 2012
-Birinapant Demonstrates Significant Anti-Cancer Effect in Patient-Derived Primary Pancreatic Adenocarcinoma Explant Model-
-- Combination of Birinapant and TRAIL Synergistically Induce Apoptosis of Germinal Center/Follicular B Lymphoma Cells --
MALVERN, Pa.--(BUSINESS WIRE)--Apr 3, 2012 - TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that new preclinical data on its Smac mimetic drug candidate birinapant (formerly TL32711) were presented this week at the 103rd American Association for Cancer Research (AACR) Annual Meeting in Chicago. Birinapant has entered Phase 2 clinical trials for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing.
In a poster entitled “TL32711, a novel Smac mimetic, exerts significant anti-tumor efficacy in primary pancreatic adenocarcinoma model” (Abstract # 1939), the in vivo efficacy of birinapant and the relationship to birinapant's pharmacokinetic profile were evaluated in a patient-derived primary pancreatic cancer explant model that mirrors the disease's biological heterogeneity. Birinapant demonstrated significant single agent efficacy in pancreatic cancer that correlated with intra-tumor drug exposure that is achievable with doses used in the Phase 1 trial.
In a poster entitled “Smac mimetic TL32711 and TRAIL synergistically induce apoptosis of germinal center B lymphoma cells” (Abstract # 3857), the pro-apoptotic effects of birinapant, alone and in combination with TRAIL, to activate the extrinsic apoptosis pathway in a panel of B cell lymphoma cell lines were investigated. Birinapant in combination with TRAIL at low concentrations showed marked apoptosis and caspase activation in germinal center (GC) lines. GC subtypes, including follicular lymphoma, transformed follicular lymphoma and GC-diffuse large B cell lymphoma were sensitive to birinapant and TRAIL at clinically achievable birinapant concentrations, with supra-additive combination effects.
Birinapant (formerly TL32711) is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases), an endogenous regulator of apoptotic cell death that selectively antagonizes multiple Inhibitor of Apoptosis Proteins (IAPs). Birinapant has entered Phase 2 clinical development for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing. In the clinical studies to date, birinapant has been well tolerated and exhibited rapid suppression of IAPs and antitumor activity.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.
James Goldschmidt, Ph.D.
Rx Communications Group, LLC
Eric Goldman, 917-322-2563
Posted: April 2012